Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun:63 Suppl 1:S170-S175.
doi: 10.1002/jcph.2224.

Landscape and Regulatory Perspective on Oncology Drugs in Pregnancy

Ruby Leong  1 , Manuela Grimstein  1 , Peter DeMaria  2 , Kelly J Norsworthy  2 , Elimika Pfuma Fletcher  1 , Stacy Shord  1
Affiliations

Landscape and Regulatory Perspective on Oncology Drugs in Pregnancy

Ruby Leong et al. J Clin Pharmacol. 2023 Jun.

Abstract

Cancers affecting pregnant women include breast cancer, melanoma, thyroid cancer, cervical cancer, lymphomas, and leukemias. The medical management of cancer during pregnancy with molecularly targeted oncology drugs remains quite challenging, with knowledge gaps about the drugs' safety and efficacy due to exclusion of pregnant women from cancer clinical trials, discontinuation of individuals who become pregnant during clinical trials, and limited information on appropriate dosing of molecularly targeted oncology drugs during pregnancy. Physiological changes occur during pregnancy and may result in alterations in the absorption, distribution, metabolism, and excretion of drugs used in pregnant women. Physiologically based pharmacokinetic modeling that incorporates physiological changes induced by both the cancer disease state and pregnancy has the potential to inform dosing of molecularly targeted oncology drugs for pregnant women, improve our understanding of the pharmacokinetic changes associated with pregnancy in patients with cancer, facilitate the design of potential studies of molecularly targeted oncology drugs in pregnant women to support dosing recommendations, and provide model-informed pharmacokinetic data to support regulatory decision making.

Keywords: Clinical Pharmacology (CPH); Oncology (ONC); PBPK; Special Populations; Women's Health.

PubMed Disclaimer

References

    1. Mathews TJ, Hamilton BE. Mean age of mothers is on the rise: United States, 2000-2014. NCHS data brief. 2016;(232):1-8.
    1. McCormick A, Peterson E. Cancer in pregnancy. Obstet Gynecol Clin North Am. 2018;45(2):187-200.
    1. Miyamoto S, Yamada M, Kasai Y, Miyauchi A, Andoh K. Anticancer drugs during pregnancy. Jpn J Clin Oncol. 2016;46(9):795-804.
    1. Assi R, Kantarjian H, Keating M, et al. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-center experience. Leuk Lymphoma. 2021;62(4):909-917.
    1. Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015;90(12):1111-1115.

LinkOut - more resources